MediPharm Labs Corp.
LABS.TOTSXHealthcare● Active
$0.08
+$0.01(+7.14%)
Market Cap$31864800
P/E Ratio—
52W High$0.1
52W Low$0.06
MediPharm Labs Corp. (LABS.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LABS.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.00
Est. -$0.00 · +41.2%
Revenue
$0.01B
Est. $0.01B · +3.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
LABS.TO reports quarterly as a TSX-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.00 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.00 | -$0.00 | +41.2% | $0.01B | $0.01B | +3.1% |
| ▼ Q1 FY2026 | Mar 30, 2026 | -$0.00 | -$0.00 | -95.7% | $0.01B | $0.01B | +18.9% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.00 | -$0.01 | -69.7% | $0.01B | $0.01B | -3.2% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.00 | -$0.01 | -566.7% | $0.01B | $0.01B | +7.3% |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.00 | -$0.01 | -194.1% | $0.01B | $0.01B | -2.6% |
| — Q1 FY2025 | Mar 27, 2025 | — | -$0.00 | — | $0.01B | $0.01B | +10.5% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.00 | -$0.01 | -212.5% | $0.01B | $0.01B | -10.1% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.00
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.00
EPS Est.
-$0.00
EPS Surpr.
+41.2%
Revenue
$0.01B
Q1 FY2026
Mar 30, 2026Miss
EPS Actual
-$0.00
EPS Est.
-$0.00
EPS Surpr.
-95.7%
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.01
EPS Est.
-$0.00
EPS Surpr.
-69.7%
Revenue
$0.01B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.01
EPS Est.
-$0.00
EPS Surpr.
-566.7%
Revenue
$0.01B
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.01
EPS Est.
-$0.00
EPS Surpr.
-194.1%
Revenue
$0.01B
Q1 FY2025
Mar 27, 2025
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.01
EPS Est.
-$0.00
EPS Surpr.
-212.5%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q3 FY2026 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q2 FY2026 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q1 FY2026 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q4 FY2025 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q3 FY2025 | $-0.00 | $-0.00 | $-0.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +41.2% | $0.08 | $0.09 | +12.50% |
| ▼ Q1 FY2026 | Mar 30, 2026 | -95.7% | $0.07 | $0.07 | +0.00% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -69.7% | $0.07 | $0.07 | +0.00% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -566.7% | $0.09 | $0.08 | -11.11% |
| ▼ Q2 FY2025 | May 15, 2025 | -194.1% | $0.10 | $0.10 | -5.00% |
| — Q1 FY2025 | Mar 27, 2025 | — | $0.10 | $0.10 | +0.00% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -212.5% | $0.08 | $0.07 | -12.50% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +0.0% | $0.07 | $0.07 | +0.00% |
Q2 FY2026+12.50%
Report Date
May 13, 2026
EPS Beat/Miss
+41.2%
Price Before
$0.08
Price After
$0.09
Q1 FY2026+0.00%
Report Date
Mar 30, 2026
EPS Beat/Miss
-95.7%
Price Before
$0.07
Price After
$0.07
Q4 FY2025+0.00%
Report Date
Nov 13, 2025
EPS Beat/Miss
-69.7%
Price Before
$0.07
Price After
$0.07
Q3 FY2025-11.11%
Report Date
Aug 14, 2025
EPS Beat/Miss
-566.7%
Price Before
$0.09
Price After
$0.08
Q2 FY2025-5.00%
Report Date
May 15, 2025
EPS Beat/Miss
-194.1%
Price Before
$0.10
Price After
$0.10
Q1 FY2025+0.00%
Report Date
Mar 27, 2025
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.10
Q4 FY2024-12.50%
Report Date
Nov 14, 2024
EPS Beat/Miss
-212.5%
Price Before
$0.08
Price After
$0.07
Q3 FY2024+0.00%
Report Date
Aug 14, 2024
EPS Beat/Miss
+0.0%
Price Before
$0.07
Price After
$0.07
Avg Beat Reaction+6.25%
Avg Miss Reaction-5.72%
Beat Rate2 / 8 quarters
Largest Move+12.50% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LABS.TO ends December
MediPharm Labs Corp. (LABS.TO) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.00 — beating the analyst consensus of $-0.00 by +41.2%. The next LABS.TO earnings date is expected around September 1, 2026.
Each quarter, investors track LABS.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LABS.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LABS.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LABS.TO earnings · 5 questionsMediPharm Labs Corp.'s next earnings report is expected around September 1, 2026. LABS.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LABS.TO historically reports after market close (AMC).
LABS.TO earnings datewhen is LABS.TO earningsLABS.TO next earnings datewhen does LABS.TO report earningsLABS.TO earnings calendar
▸ Source: FMP · MediPharm Labs Corp. SEC filings · US GAAP · MediPharm Labs Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026